Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer

Science Signaling

Volumn 7, Issue 322, 2014, Pages

  Lai, Andrea Z ^a,b   Cory, Sean ^b,c   Zhao, Hong ^a,b   Gigoux, Mathieu ^b   Monast, Anie ^b   Guiot, Marie Christine ^a,d   Huang, Sidong ^a,b   Tofigh, Ali ^b,c   Thompson, Crista ^b   Naujokas, Monica ^b   Marcus, Victoria A ^a   Bertos, Nicholas ^a,b   Sehat, Bita ^b   Perera, Rushika M ^a,b   Bell, Emily S ^a,b   Page, Brent D G ^e   Gunning, Patrick T ^e   Ferri, Lorenzo E ^a   Hallett, Michael ^b,c   Park, Morag ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; BP 1102; CRIZOTINIB; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 4; EMD 1214063; IMATINIB; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN FOS; PROTEIN KINASE B; RAPAMYCIN; RUXOLITINIB; S 3I 201; SCATTER FACTOR RECEPTOR; SH 54; SORAFENIB; STAT3 PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; DUAL SPECIFICITY PHOSPHATASE 6; DUSP4 PROTEIN, HUMAN; DUSP6 PROTEIN, HUMAN; MET PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; STAT3 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; STOMACH CANCER; WESTERN BLOTTING; DRUG RESISTANCE; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DUAL SPECIFICITY PHOSPHATASE 6; DUAL-SPECIFICITY PHOSPHATASES; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-MET; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 84899075735     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004839     Document Type: Article

References (96)

1. B. Lutterbach, Q. Zeng, L. J. Davis, H. Hatch, G. Hang, N. E. Kohl, J. B. Gibbs, B. S. Pan, Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67, 2081-2088 (2007).
2. G. A. Smolen, R. Sordella, B. Muir, G. Mohapatra, A. Barmettler, H. Archibald, W. J. Kim, R. A. Okimoto, D. W. Bell, D. C. Sgroi, J. G. Christensen, J. Settleman, D. A. Haber, Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U.S.A. 103, 2316-2321 (2006).
3. U. Fischer, H. W. Müller, H. P. Sattler, K. Feiden, K. D. Zang, E. Meese, Amplification of the MET gene in glioma. Genes Chromosomes Cancer 12, 63-65 (1995).
4. S. Garcia, J. P. Dalès, J. Jacquemier, E. Charafe-Jauffret, D. Birnbaum, L. Andrac-Meyer, M. N. Lavaut, C. Allasia, S. Carpentier-Meunier, P. Bonnier, C. Charpin-Taranger, c-Met overexpression in inflammatory breast carcinomas: Automated quantification on tissue microarrays. Br. J. Cancer 96, 329-335 (2007).
5. D. Matsubara, S. Ishikawa, S. Oguni, H. Aburatani, M. Fukayama, T. Niki, Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J. Thorac. Oncol. 5, 1317-1324 (2010).
6. E. Gherardi, W. Birchmeier, C. Birchmeier, G. V. Woude, Targeting MET in cancer: Rationale and progress. Nat. Rev. Cancer 12, 89-103 (2012).
7. K. H. Jung, B. H. Park, S. S. Hong, Progress in cancer therapy targeting c-Met signaling pathway. Arch. Pharm. Res. 35, 595-604 (2012).
8. A. Z. Lai, J. V. Abella, M. Park, Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 19, 542-551 (2009).
9. C. Birchmeier, W. Birchmeier, E. Gherardi, G. F. Vande Woude, Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915-925 (2003).
10. J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C. M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Jänne, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
11. J. Bean, C. Brennan, J. Y. Shih, G. Riely, A. Viale, L. Wang, D. Chitale, N. Motoi, J. Szoke, S. Broderick, M. Balak, W. C. Chang, C. J. Yu, A. Gazdar, H. Pass, V. Rusch, W. Gerald, S. F. Huang, P. C. Yang, V. Miller, M. Ladanyi, C. H. Yang, W. Pao, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U.S.A. 104, 20932-20937 (2007).
12. C. Birchmeier, E. Gherardi, Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8, 404-410 (1998).
13. P. Peschard, T. M. Fournier, L. Lamorte, M. A. Naujokas, H. Band, W. Y. Langdon, M. Park, Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004 (2001).
14. J. V. Abella, P. Peschard, M. A. Naujokas, T. Lin, C. Saucier, S. Urbé, M. Park, Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell. Biol. 25, 9632-9645 (2005).
15. D. E. Hammond, S. Urbé, G. F. Vande Woude, M. J. Clague, Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 20, 2761-2770 (2001).
16. R. Onozato, T. Kosaka, H. Kuwano, Y. Sekido, Y. Yatabe, T. Mitsudomi, Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J. Thorac. Oncol. 4, 5-11 (2009).
17. M. Kong-Beltran, S. Seshagiri, J. Zha, W. Zhu, K. Bhawe, N. Mendoza, T. Holcomb, K. Pujara, J.Stinson, L. Fu,C.Severin, L.Rangell, R. Schwall, L. Amler, D. Wickramasinghe, R. Yauch, Somatic mutations lead to an oncogenic deletion of Met in lung cancer. Cancer Res. 66, 283-289 (2006).
18. A. Lorenzato, M. Olivero, S. Patanè, E. Rosso, A. Oliaro, P. M. Comoglio, M. F. Di Renzo, Novel somatic mutations of the MET oncogene in human carcinomametastases activating cell motility and invasion. Cancer Res. 62, 7025-7030 (2002).
19. H. H. L. Mak, P. Peschard, T. Lin, M. A. Naujokas, D. Zuo, M. Park, Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Oncogene 26, 7213-7221 (2007).
20. A. Z. Lai, M. Durrant, D. Zuo, C. D. H. Ratcliffe, M. Park, Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer. J. Biol. Chem. 287, 8048-8059 (2012).
21. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, D. M. Parkin, GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide, IARC CancerBase No. 10 (International Agency for Research on Cancer, Lyon, France, 2010), pp. 1-7; http://globocan.iarc.fr.
22. H. Kuniyasu, W. Yasui, Y. Kitadai, H. Yokozaki, H. Ito, E. Tahara, Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun. 189, 227-232 (1992).
23. K. Tsugawa, Y. Yonemura, Y. Hirono, S. Fushida, M. Kaji, K. Miwa, I. Miyazaki, H. Yamamoto, Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: Correlation to clinical features. Oncology 55, 475-481 (1998).
24. J. Houldsworth, C. Cordon-Cardo, M. Ladanyi, D. P. Kelsen, R. S. Chaganti, Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res. 50, 6417-6422 (1990).
25. C. Sakakura, T. Mori, T. Sakabe, Y. Ariyama, T. Shinomiya, K. Date, A. Hagiwara, T. Yamaguchi, T. Takahashi, Y. Nakamura, T. Abe, J. Inazawa, Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 24, 299-305 (1999).
26. M. Nessling, S. Solinas-Toldo, K. K. Wilgenbus, F. Borchard, P. Lichter, Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer 23, 307-316 (1998).
27. M. Nakajima, H. Sawada, Y. Yamada, A. Watanabe, M. Tatsumi, J. Yamashita, M. Matsuda, T. Sakaguchi, T. Hirao, H. Nakano, The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85, 1894-1902 (1999).
28. F. Carneiro, M. Sobrinho-Simoes, The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 88, 238-240 (2000).
29. U. Drebber, S. E. Baldus, B. Nolden, G. Grass, E. Bollschweiler, H. P. Dienes, A. H. Hölscher, S. P. Mönig, The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol. Rep. 19, 1477-1483 (2008).
30. B. J. Dicken, D. L. Bigam, C. Cass, J. R. Mackey, A. A. Joy, S. M. Hamilton, Gastric adenocarcinoma: Review and considerations for future directions. Ann. Surg. 241, 27-39 (2005).
31. S. Peters, A. A. Adjei, MET: A promising anticancer therapeutic target. Nat. Rev. Clin. Oncol. 9, 314-326 (2012).
32. J. K. Lennerz, E. L. Kwak, A. Ackerman, M. Michael, S. B. Fox, K. Bergethon, G. Y. Lauwers, J. G. Christensen, K. D. Wilner, D. A. Haber, R. Salgia, Y. J. Bang, J. W. Clark, B. J. Solomon, A. J. Iafrate, MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29, 4803-4810 (2011).
33. W. Okamoto, I. Okamoto, T. Arao, K. Kuwata, E. Hatashita, H. Yamaguchi, K. Sakai, K. Yanagihara, K. Nishio, K. Nakagawa, Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol. Cancer Ther. 11, 1557-1564 (2012).
34. L. E. Ferri, S. Ades, T. Alcindor, M. Chasen, V. Marcus, M. Hickeson, G. Artho, M. P. Thirlwell, Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: A multicenter phase II trial. Ann. Oncol. 23, 1512-1517 (2012).
35. C. R. Graveel, J. D. DeGroot, Y. Su, J. Koeman, K. Dykema, S. Leung, J. Snider, S. R. Davies, P. J. Swiatek, S. Cottingham, M. A. Watson, M. J. Ellis, R. E. Sigler, K. A. Furge, G. F. Vande Woude, Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc. Natl. Acad. Sci. U.S.A. 106, 12909-12914 (2009).
36. T. Oshima, M. Masuda, Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg. Today 42, 313-327 (2012).
37. W. Okamoto, I. Okamoto, T. Arao, K. Yanagihara, K. Nishio, K. Nakagawa, Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Br. J. Cancer 105, 407-412 (2011).
38. J. G. Christensen, R. Schreck, J. Burrows, P. Kuruganti, E. Chan, P. Le, J. Chen, X. Wang, L. Ruslim, R. Blake, K. E. Lipson, J. Ramphal, S. Do, J. J. Cui, J. M. Cherrington, D. B. Mendel, A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63, 7345-7355 (2003).
39. E. L. Kwak, Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. I. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist,W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
40. B. N. Chau, J. Y. J. Wang, Coordinated regulation of life and death by RB. Nat. Rev. Cancer 3, 130-138 (2003).
41. I. Amit, A. Citri, T. Shay, Y. Lu, M. Katz, F. Zhang, G. Tarcic, D. Siwak, J. Lahad, J. Jacob-Hirsch, N. Amariglio, N. Vaisman, E. Segal, G. Rechavi, U. Alon, G. B. Mills, E. Domany, Y. Yarden, A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 39, 503-512 (2007).
42. I. Amit, R. Wides, Y. Yarden, Evolvable signaling networks of receptor tyrosine kinases: Relevance of robustness to malignancy and to cancer therapy. Mol. Syst. Biol. 3, 151 (2007).
43. M. Sachs, H. Brohmann, D. Zechner, T. Müller, J. Hülsken, I. Walther, U. Schaeper, C. Birchmeier, W. Birchmeier, Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 150, 1375-1384 (2000).
44. K. M. Weidner, S. Di Cesare, M. Sachs, V. Brinkmann, J. Behrens, W. Birchmeier, Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384, 173-176 (1996).
45. C. R. Maroun, M. Holgado-Madruga, I. Royal, M. A. Naujokas, T. M. Fournier, A. J. Wong, M. Park, The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 19, 1784-1799 (1999).
46. C. R. Maroun, M. A. Naujokas, M. Holgado-Madruga, A. J. Wong, M. Park, The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the Met receptor tyrosine kinase. Mol. Cell. Biol. 20, 8513-8525 (2000).
47. U. Schaeper, N. H. Gehring, K. P. Fuchs, M. Sachs, B. Kempkes, W. Birchmeier, Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol. 149, 1419-1432 (2000).
48. M. Rosário, W. Birchmeier, How to make tubes: Signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 13, 328-335 (2003).
49. X. Zhang, N. Tang, T. J. Hadden, A. K. Rishi, Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta. 1813, 1978-1986 (2011).
50. K. A. Furge, Y. W. Zhang, G. F. Vande Woude, Met receptor tyrosine kinase: Enhanced signaling through adapter proteins. Oncogene 19, 5582-5589 (2000).
51. R. Buettner, L. B. Mora, R. Jove, Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8, 945-954 (2002).
52. D. J. Dauer, B. Ferraro, L. Song, B. Yu, L. Mora, R. Buettner, S. Enkemann, R. Jove, E. B. Haura, Stat3 regulates genes common to both wound healing and cancer. Oncogene 24, 3397-3408 (2005).
53. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).
54. ENCODE Project Consortium, A user's guide to the encyclopedia of DNA elements (ENCODE). PLOS Biol. 9, e1001046 (2011).
55. H. Z. Chen, S. Y. Tsai, G. Leone, Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat. Rev. Cancer 9, 785-797 (2009).
56. K. I. Patterson, T. Brummer, P. M. O'Brien, R. J. Daly, Dual-specificity phosphatases: Critical regulators with diverse cellular targets. Biochem. J. 418, 475-489 (2009).
57. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-Outmezguine, O. Grbovic-Huezo, V. Serra, P. K. Majumder, J. Baselga, N. Rosen, AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71 (2011).
58. R. B. Corcoran, H. Ebi, A. B. Turke, E. M. Coffee, M. Nishino, A. P. Cogdill, R. D. Brown, P. Della Pelle, D. Dias-Santagata, K. E. Hung, K. T. Flaherty, A. Piris, J. A. Wargo, J. Settleman, M. Mino-Kenudson, J. A. Engelman, EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
59. V. Yadav, X. Zhang, J. Liu, S. Estrem, S. Li, X. Q. Gong, S. Buchanan, J. R. Henry, J. J. Starling, S. B. Peng, Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J. Biol. Chem. 287, 28087-28098 (2012).
60. S. Meng, Z. Chen, T. Munoz-Antonia, J. Wu, Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. Biochem. J. 391, 143-151 (2005).
61. K. Nishida, T. Hirano, The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci. 94, 1029-1033 (2003).
62. P. Peschard, M. Park, From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26, 1276-1285 (2007).
63. L. Lamorte, I. Royal, M. Naujokas, M. Park, Crk adapter proteins promote an epithelial- mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol. Biol. Cell 13, 1449-1461 (2002).
64. R. Roskoski Jr., ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol. Res. 66, 105-143 (2012).
65. R. Roskoski Jr., MEK1/2 dual-specificity protein kinases: Structure and regulation. Biochem. Biophys. Res. Commun. 417, 5-10 (2012).
66. C. M. Johannessen, J. S. Boehm, S. Y. Kim, S. R. Thomas, L. Wardwell, L. A. Johnson, C. M. Emery, N. Stransky, A. P. Cogdill, J. Barretina, G. Caponigro, H. Hieronymus, R. R. Murray, K. Salehi-Ashtiani, D. E. Hill, M. Vidal, J. J. Zhao, X. Yang, O. Alkan, S. Kim, J. L. Harris, C. J. Wilson, V. E. Myer, P. M. Finan, D. E. Root, T. M. Roberts, T. Golub, K. T. Flaherty, R. Dummer, B. L. Weber,W. R. Sellers, R. Schlegel, J. A. Wargo, W. C. Hahn, L. A. Garraway, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2011).
67. C. Boccaccio, M. Andò, L. Tamagnone, A. Bardelli, P. Michieli, C. Battistini, P. M. Comoglio, Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391, 285-288 (1998).
68. H. H. Hartgrink, E. P. Jansen, N. C. van Grieken, C. J. van de Velde, Gastric cancer. Lancet 374, 477-490 (2009).
69. D. Cunningham, W. H. Allum, S. P. Stenning, J. N. Thompson, C. J. H. Van de Velde, M. Nicolson, J. H. Scarffe, F. J. Lofts, S. J. Falk, T. J. Iveson, D. B. Smith, R. E. Langley, M. Verma, S. Weeden, Y. J. Chua; MAGIC Trial Participants, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11-20 (2006).
70. D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A. R. Norman; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom, Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36-46 (2008).
71. E. Van Cutsem, V. M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, A. Rodrigues, M. Fodor, Y. Chao, E. Voznyi, M. L. Risse, J. A. Ajani; V325 Study Group, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J. Clin. Oncol. 24, 4991-4997 (2006).
72. S. Sakuramoto, M. Sasako, T. Yamaguchi, T. Kinoshita, M. Fujii, A. Nashimoto, H. Furukawa, T. Nakajima, Y. Ohashi, H. Imamura, M. Higashino, Y. Yamamura, A. Kurita, K. Arai; ACTS-GC Group, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810-1820 (2007).
73. Y. J. Bang, E. Van Cutsem, A. Feyereislova, H. C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Rüschoff, Y. K. Kang; ToGA Trial Investigators, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
74. A. Guo, J. Villen, J. Kornhauser, K. A. Lee, M. P. Stokes, K. Rikova, A. Possemato, J. Nardone, G. Innocenti, R. Wetzel, Y. Wang, J. MacNeill, J. Mitchell, S. P. Gygi, J. Rush, R. D. Polakiewicz, M. J. Comb, Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. U.S.A. 105, 692-697 (2008).
75. A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, J. A. Hickman, P. M. Comoglio, L. Trusolino, Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci. Signal. 2, ra80 (2009).
76. F. Bladt, B. Faden, M. Friese-Hamim, C. Knuehl, C. Wilm, C. Fittschen, U. Grädler, M. Meyring, D. Dorsch, F. Jaehrling, U. Pehl, F. Stieber, O. Schadt, A. Blaukat, EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin. Cancer Res. 19, 2941-2951 (2013).
77. Z. A. Syed, W. Yin, K. Hughes, J. N. Gill, R. Shi, J. L. Clifford, HGF/c-met/Stat3 signaling during skin tumor cell invasion: Indications for a positive feedback loop. BMC Cancer 11, 180 (2011).
78. S. Chandarlapaty, Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov. 2, 311-319 (2012).
79. D. L. Krebs, D. J. Hilton, SOCS proteins: Negative regulators of cytokine signaling. Stem Cells 19, 378-387 (2001).
80. U. McDermott, R. V. Pusapati, J. G. Christensen, N. S. Gray, J. Settleman, Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res. 70, 1625-1634 (2010).
81. J. Qi, M. A. McTigue, A. Rogers, E. Lifshits, J. G. Christensen, P. A. Jänne, J. A. Engelman, Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 71, 1081-1091 (2011).
82. N. V. Lee, M. E. Lira, A. Pavlicek, J. Ye, D. Buckman, S. Bagrodia, S. P. Srinivasa, Y. Zhao, S. Aparicio, P. A. Rejto, J. G. Christensen, K. A. Ching, K. Smalley, A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through MAPK activation. PLOS One 7, e39653 (2012).
83. R. Dillon, C. L. Nilsson, S. D. H. Shi, N. V. Lee, B. Krastins, M. J. Greig, Discovery of a novel B-Raf fusion protein related to c-Met drug resistance. J. Proteome Res. 10, 5084-5094 (2011).
84. V. Cepero, J. R. Sierra, S. Corso, E. Ghiso, L. Casorzo, T. Perera, P. M. Comoglio, S. Giordano, MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 70, 7580-7590 (2010).
85. A. Piscazzi, E. Costantino, F. Maddalena, M. I. Natalicchio, A. M. T. Gerardi, R. Antonetti, M. Cignarelli, M. Landriscina, Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 97, E898-E906 (2012).
86. M. H. Huang, J. H. Lee, Y. J. Chang, H. H. Tsai, Y. L. Lin, A. M. Y. Lin, J. C. H. Yang, MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol. Oncol. 7, 112-120 (2013).
87. K. Ohashi, L. V. Sequist, M. E. Arcila, T. Moran, J. Chmielecki, Y. L. Lin, Y. Pan, L. Wang, E. de Stanchina, K. Shien, K. Aoe, S. Toyooka, K. Kiura, L. Fernandez-Cuesta, P. Fidias, J. C. H. Yang, V. A. Miller, G. J. Riely, M. G. Kris, J. A. Engelman, C. L. Vnencak-Jones, D. Dias-Santagata, M. Ladanyi, W. Pao, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl. Acad. Sci. U.S.A. 109, E2127-E2133 (2012).
88. S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, E. Valtorta, R. Schiavo, M. Buscarino, G. Siravegna, K. Bencardino, A. Cercek, C. T. Chen, S. Veronese, C. Zanon, A. Sartore-Bianchi, M. Gambacorta, M. Gallicchio, E. Vakiani, V. Boscaro, E. Medico, M. Weiser, S. Siena, F. Di Nicolantonio, D. Solit, A. Bardelli, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
89. J. S. Duncan, M. C. Whittle, K. Nakamura, A. N. Abell, A. A. Midland, J. S. Zawistowski, N. L. Johnson, D. A. Granger, N. V. Jordan, D. B. Darr, J. Usary, P. F. Kuan, D. M. Smalley, B. e. n. Major, X. He, K. A. Hoadley, B. Zhou, N. E. Sharpless, C. M. Perou, W. Y. Kim, S. M. Gomez, X. Chen, J. Jin, S. V. Frye, H. S. Earp, L. M. Graves, G. L. Johnson, Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triplenegative breast cancer. Cell 149, 307-321 (2012).
90. P. I. Poulikakos, C. Zhang, G. Bollag, K. M. Shokat, N. Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
91. S. J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, N. Dhomen, J. Hussain, J. S. Reis-Filho, C. J. Springer, C. Pritchard, R. Marais, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
92. N. Normanno, A. D. Luca, M. R. Maiello, M. Campiglio, M. Napolitano, M. Mancino, A. Carotenuto, G. Viglietto, S. Menard, The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J. Cell. Physiol. 207, 420-427 (2006).
93. X. Zhang, P. Yue, B. D. G. Page, T. Li, W. Zhao, A. T. Namanja, D. Paladino, J. Zhao, Y. Chen, P. T. Gunning, J. Turkson, Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl. Acad. Sci. U.S.A. 109, 9623-9628 (2012).
94. N. Deng, L. K. Goh, H. Wang, K. Das, J. Tao, I. B. Tan, S. Zhang, M. Lee, J. Wu, K. H. Lim, Z. Lei, G. Goh, Q. Y. Lim, A. L. K. Tan, D. Y. Sin Poh, S. Riahi, S. Bell, M. M. Shi, R. Linnartz, F. Zhu, K. G.Yeoh, H. C. Toh,W. P. Yong, H. C. Cheong,S. Y.Rha, A. Boussioutas, H. Grabsch, S. Rozen, P. Tan, A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61, 673-684 (2012).
95. A. M. Dulak, S. E. Schumacher, J. van Lieshout, Y. Imamura, C. Fox, B. Shim, A. H. Ramos, G. Saksena, S. C. Baca, J. Baselga, J. Tabernero, J. Barretina, P. C. Enzinger, G. Corso, F. Roviello, L. Lin, S. Bandla, J. D. Luketich, A. Pennathur, M. Meyerson, S. Ogino, R. A. Shivdasani, D. G. Beer, T. E. Godfrey, R. Beroukhim, A. J. Bass, Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383-4393 (2012).
96. G. A. Rodrigues, M. A. Naujokas, M. Park, Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol. Cell. Biol. 11, 2962-2970 (1991).